Current Study: K6

Purpose:
• The primary purpose of this study is to determine the pharmacokinetics of a single dose of an investigational product in participants living with severe renal impairment or end-stage kidney disease (ESKD) compared with participants with normal renal function.
• Information regarding safety and side effects that may occur will also be collected.
• This study is for research purposes only and is not intended to treat your kidney disease.

Method of Administration: Single injectable dose of study drug

Investigator: Thomas Marbury, MD

To qualify:

• 18 to 85 years old
• Must have kidney impairment or disease. May also be on dialysis.
• May be seeing a nephrologist, have reduced kidney function, or low creatinine clearance and taking medicine such as:

• Procrit®, Epogen®, or Aranesp® for low blood count
or
• PhosLo for high blood phosphorus

Length/Duration:
• 5 days and 4 nights in our research facility
• 7 follow-up visits

Location: 5055 South Orange Avenue, Orlando, FL 32809

Compensation:
Qualified participants will receive study medication, study related physical exams and laboratory tests

Qualified participants will be compensated up to $4,200 for time and travel

Whom to Contact: Recruitment Department: 407-240-7876